• 

  An orally bioavailable Chkl inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation 

  Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; Schick, U; Hafsi, H; Thompson, A; Khoo, V; Harrington, K; Zaidi, S (2017-03)
• 

  Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. 

  Vyse, S; Howitt, A; Huang, PH (2017-05-03)

  Despite the recent approval of third-generation therapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small cell lung cancer. Conceptually, synthetic lethality ...
• 

  Low-risk Prostate Cancer: Identification, Management, and Outcomes. 

  Moschini, M; Carroll, PR; Eggener, SE; Epstein, JI; Graefen, M; Montironi, R; Parker, C (2017-03-15)

  CONTEXT: The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. OBJECTIVE: In this collaborative review article, we examine recent literature regarding low-risk ...
• 

  An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. 

  Sartor, O; Coleman, RE; Nilsson, S; Heinrich, D; Helle, SI; O'Sullivan, JM; Vogelzang, NJ; Bruland, Ø; Kobina, S; Wilhelm, S; Xu, L; Shan, M; Kattan, MW; Parker, C (2017-02-16)
• 

  VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland 

  Hussain, SA; Ansari, J; Huddart, R; Powers, DG; Lyons, J; Wylie, J; Vilarino-Varlela, M; Elander, NO; McMenemin, R; Pickering, LM; Faust, G; Chauhan, S; Jackson, RJ (2017-03)

View more